Daily FNArena News - Australia

FNArena’s weekly update on short positions in the Australian share market.

Several brokers are of the opinion Aurizon could do more with its capital structure. Credit Suisse initiates coverage on this basis.

Disappointing earnings results were one reason a stampede began out of Australia’s big banks, but having fallen this far, is value now emerging?

South32 has commenced trading on ASX and several brokers line up to analyse the outlook for the new resources company.

First half results for Dulux Group were mixed and brokers are somewhat divided as the outlook lacks clarity.

Weekly update on recommendation, target price, and earnings forecast changes.

Sirtex Medical has released data from its SIRFLOX study with some statistically significant outcomes in the treatment of liver cancer.

ResMed has revealed adverse findings from its SERVE-HF trial. While limited to a specific group, brokers concede a lost growth opportunity.

FNArena’s weekly update on short positions in the Australian share market.

FNArena provides a weekly update of Australian listed corporate bond issues, current pricing and yield data.